Ortho Regenerative Technologies
-
Sports Medicine
Ortho Regenerative Technologies Announces Enrollment of First Patient in its U.S. Phase l/ll Rotator Cuff Tear Repair Clinical Trial
First patient surgery completed; additional surgeries already scheduled8 clinical centres now fully initiated and recruiting / screening for patients MONTREAL, July…
Read More » -
Biologics
Ortho Regenerative Technologies Initiates Patients Recruitment For Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial
Contracting procedures completed for 6 of the 10 clinical trial sites5 sites fully activated, with ongoing patients’ screening and recruitment…
Read More » -
Regulatory
Ortho Regenerative Technologies Receives Key U.S. Composition and Method Patent for Ortho-R Soft Tissue Repair Platform
New patent issued by U.S. Patent and Trademark Office to protect core IP until 2035Positions Company as leading player in…
Read More » -
Financial
Ortho Regenerative Technologies Closes Oversubscribed Non-Brokered Private Placement for $3.2 Million
Proceeds to be used to accelerate the ORTHO-R Phase I/II US Clinical trial for rotator cuff tear repairInsiders contribute approximately $560,000 MONTREAL, April…
Read More » -
Biologics
Ortho Regenerative Technologies Announces Executive Leadership Changes
Philippe Deschamps appointed President and CEOFirst patient enrolment into the U.S. ORTHO-R Phase I / II clinical trial still imminent. MONTREAL, March…
Read More » -
Financial
Ortho Regenerative Technologies Announces $3 Million Non-Brokered Private Placement of Units
MONTREAL, Feb. 11, 2022 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) (“Ortho” or the “Company“), a clinical-stage orthobiologics company focused on…
Read More » -
Biologics
Ortho Regenerative Technologies Enters Into A Material Transfer Agreement With A Global Strategic Medical Company For Its Ortho-R Rotator Cuff Tear Repair Phase I/II U.S. Clinical Trial
MONTREAL, Feb. 7, 2022 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) (“Ortho” or the “Company“), a clinical-stage orthobiologics company focused on…
Read More » -
Biologics
Ortho Regenerative Technologies Announces U.S. IND Clinical Hold Lifted By The FDA & Clearance To Proceed With U.S. Clinical Trial
MONTREAL, Dec. 13, 2021 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) (“Ortho” or the “Company”), a clinical-stage orthobiologics company focused on the…
Read More » -
Biologics
Ortho Regenerative Technologies Announces Extension of FDA Clinical Hold of ORTHO-R Investigational New Drug Application
Most complex, and majority of additional information on characterization at point of care and CMC related data submitted accepted by…
Read More » -
Biologics
Ortho Regenerative Technologies Receives Clinical Hold Letter From the U.S. FDA
Additional CMC related data and characterization requested by the FDACompany confident of providing requested information over the coming weeksPhase I/II…
Read More » -
Biologics
Ortho Regenerative Technologies Adds Patrick O’Donnell to Board of Directors
MONTREAL, Feb. 24, 2021 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) (“Ortho RTI” or the “Company“), a clinical stage orthobiologics company…
Read More » -
Biologics
Ortho Regenerative Technologies Enters Into Global License With Hanuman Pelican, Inc.
Provides Ortho RTI with worldwide rights to commercialize Buoy Suspension Fractional System in combination with Ortho-RProvides Ortho RTI with Hanuman…
Read More » -
Financial
Ortho Regenerative Technologies Completes Non-Brokered $3.0 Million Private Placement
MONTREAL, Dec. 3, 2020 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) (“Ortho RTI” or the “Company“), an emerging orthobiologics company focused…
Read More » -
Biologics
Ortho Regenerative Technologies Announces the Nomination of its New Vice-president Clinical and Medical Affairs
MONTREAL, Oct. 19, 2020 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (“Ortho RTI” or the “Company“), an emerging orthobiologics company focused on…
Read More » -
Biologics
Ortho Regenerative Technologies Closes Non-Brokered $2.5 Million Private Placement
MONTREAL, Aug. 24, 2020 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (“Ortho RTI” or the “Company“), an emerging orthobiologics company focused on…
Read More »